Abstracts Archive - Page 1050 of 2425 - ACR Meeting Abstracts

Abstract Number: 681 • 2018 ACR/ARHP Annual Meeting
Identification of Treatment Naïve Patients with Psoriatic Arthritis Who Will Require a TNF Inhibitor
Dan Gromer¹, Laura C. Coates², Oliver FitzGerald³, Blanca Himes⁴, Philip Helliwell⁵ and Alexis Ogdie⁶, ¹University of Pennsylvania, Medical Student, Philadelphia, PA, ²University of Oxford, Oxford, United Kingdom, ³Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ⁴Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁵LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁶Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease that affects the skin, joints, and soft tissues. No metrics exist to indicate whether an…
Abstract Number: 682 • 2018 ACR/ARHP Annual Meeting
Nonsteroidal Anti-Inflammatory Drug Use and Hypertension in Ankylosing Spondylitis
Jean Liew¹, John D. Reveille², Michael Ward³, MinJae Lee⁴, Matthew Brown⁵, Mohammad H. Rahbar⁶, Michael Weisman⁷ and Lianne S. Gensler⁸, ¹Internal Medicine; Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ³National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ⁴Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁵Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ⁶Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, USA, Los Angeles, CA, ⁸University of California San Francisco, San Francisco, CA
Background/Purpose: Cardiovascular morbidity and mortality are increased in Ankylosing Spondylitis (AS). Nonsteroidal anti-inflammatory drugs (NSAIDs) are the first line pharmacological therapy in AS; however, their…
Abstract Number: 683 • 2018 ACR/ARHP Annual Meeting
Spanish Validation of the Gepard Questionnaire for the Detection of Psoriatic Arthritis in Argentinean Patients with Psoriasis
María Victoria Martire¹, María Paula Girard Bosch¹, Santiago Scarafia², Vanesa Laura Cosentino³, María Janina Tapia⁴, Eduardo Kerzberg³, Natalia Estrella⁵, Cristian Troitiño⁶, Josefina Marin⁷, Fernando Andres Sommerfleck⁸, Hernán Maldonado Ficco⁹, Erika Catay¹⁰, Mariana Benegas¹¹ and Enrique R Soriano¹², ¹Rheumatology, Instituto Médico Platense, La Plata, Argentina, ²Rheumatology, Instituto de Asistencia Reumatológica Integral, Buenos Aires, Argentina, ³Ramos Mejía Hospital, Buenos Aires, Argentina, ⁴Reumatology, Hospital General de Agudos José María Ramos Mejía, Buenos Aires, Argentina, ⁵Consultorio Privado, Buenos Aires, Argentina, ⁶Reumatologia, Hospital Bernardino Rivadavia, CAPITAL FEDERAL, Argentina, ⁷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁹section of Rheumatology, Clinica Regional Del Sud, Rio Cuarto, Argentina, ¹⁰Consultorios Moreno, Formosa, Argentina, ¹¹Rheumatology Section, Sanatorio Dr. Julio Méndez, Buenos Aires, Argentina, ¹²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina
Background/Purpose: Psoriatic Arthritis (PSA) is preceded by the presence of cutaneous psoriasis (PS) in approximately 80% of the cases. We consider relevant to have tools…
Abstract Number: 684 • 2018 ACR/ARHP Annual Meeting
Efficacy of Ixekizumab in Different Phenotypes of Patients with Active Psoriatic Arthritis (PsA): Results from the Spirit Trials
Frank Behrens¹, Peter Nash², Laure Gossec³, Soyi Liu Leage⁴, Inmaculada de la Torre⁵, Christophe Sapin⁴, Monika Kurzawa⁶, Gerd R. Burmester⁷ and Josef S. Smolen⁸, ¹Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany, ²University of Queensland, Brisbane, Australia, ³Sorbonne Universités, Paris, France, ⁴Lilly France, Neuilly sur Seine Cedex, France, Neuilly sur Seine Cedex, France, ⁵Eli Lilly and Company, Madrid, Spain, ⁶Eli Lilly and Company, Bad Homburg, Germany, ⁷Department of Rheumatology and Clinical Immunolgy, Charité University Hospital, Berlin, Germany, ⁸Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: PsA is a highly heterogeneous chronic inflammatory disease combining a range of musculoskeletal and extra-articular manifestations. Ixekizumab (IXE) is approved for the treatment of…
Abstract Number: 685 • 2018 ACR/ARHP Annual Meeting
Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
William FC Rigby¹, Gerd R. Burmester², Oliver FitzGerald³, Valderilio F Azevedo⁴, Peter Nash⁵, Thijs Hendrikx⁶, Daniela Graham⁷, Cunshan Wang⁷ and Thomas Jones⁶, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Charité – University Medicine Berlin, Berlin, Germany, ³Department of Rheumatology, St Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College, Dublin, Ireland, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵University of Queensland, Brisbane, Australia, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA). In most countries where tofacitinib is…
Abstract Number: 686 • 2018 ACR/ARHP Annual Meeting
Five-Year Efficacy and Safety of Apremilast Treatment in Subjects with Psa: A Pooled Analysis of the 3 Phase III Studies
Arthur Kavanaugh¹, Dafna D Gladman², Christopher J. Edwards³, Georg Schett⁴, Benoit Guerette⁵, Nikolay Delev⁵, Lichen Teng⁵, Maria Paris⁵ and Philip J. Mease⁶, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of Southampton, Southampton, United Kingdom, ⁴Friedrich-Alexander-Universität Erlangen, Nürnberg und Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Celgene Corporation, Summit, NJ, ⁶Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Long-term apremilast (APR) efficacy and safety were evaluated for up to 5 yrs in adults with active PsA in the phase III PALACE 1-3…
Abstract Number: 687 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics of Spondyloarthritis Patients in Japan in Comparison to Other Regions of the World
Haruki Sawada¹, Kazuki Yoshida², Naomi Ichikawa³, Hisashi Inoue⁴, Yuko Kaneko⁵, Taku Kawasaki⁶, Kazuo Matsui⁷, Mitsuhiro Morita⁸, Kurisu Tada⁹, Naoho Takizawa¹⁰, Naoto Tamura⁹, Atsuo Taniguchi³, Yoshinori Taniguchi¹¹, Shigeyoshi Tsujii¹², Yoichiro Haji¹³, Masei Suda¹⁴, Haruyuki Yanaoka¹⁵, Ryo Rokutanda¹⁴, Masato Okada¹⁴, Clementina López Medina¹⁶, Anna Molto¹⁷, Maxime Dougados¹⁶, Désirée van der Heijde¹⁸, Shigeto Kobayashi¹⁹, Tetsuya Tomita²⁰ and Mitsumasa Kishimoto¹⁴, ¹Immuno-rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Department of Orthopedic Surgery, Juntendo University School of Medicine, Tokyo, Japan, ⁵Department of Internal Medicine, Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁶Department of Orthopedic Surgery, Shiga University of Medical Science, Shiga, Japan, ⁷Department of Rheumatology, Tonan Hospital, Hokkaido, Japan, ⁸Department of Orthopedic Surgery, Fujita Health University, Aichi, Japan, ⁹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁰Department of Rheumatology, Chubu Rosai Hospital, Aichi, Japan, ¹¹Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi, Japan, ¹²Department of Orthopedics, Osaka Minami Medical Center, Osaka, Japan, ¹³Department of Rheumatology, Daido Hospital, Aichi, Japan, ¹⁴Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ¹⁵St. Luke's International Hospital, Tokyo, Japan, ¹⁶Department of Rheumatology, Paris Descartes University, Cochin Hospital, Paris, France, ¹⁷Department of Rheumatology, Paris Descartes University, Cochin Hospital, Paris, Japan, ¹⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁹Department of Internal Medicine, Juntendo University Koshigaya Hospital, Saitama, Japan, ²⁰Department of Orthopaedic Biomaterial Science, Osaka University Graduate School of Medicine, Osala, Japan
Background/Purpose: To delineateclinical characteristicsof patients with spondyloarthritis (SpA) in Japan in comparison to other areas of the world. Methods: Utilizingthe COMOSPA data, an international cross-sectional…
Abstract Number: 688 • 2018 ACR/ARHP Annual Meeting
Real Life Analysis of a Latin America Tertiary Spondyloarthritis Single-Center: High Frequency of Peripheral Involvement and Use of Synthetic Dmard
Andrea Shimabuco¹, Julio CB Moraes¹, Percival Sampaio-Barros², Cláudia Goldenstein-Schainberg¹, Celio R. Gonçalves¹, Ana CM Ribeiro¹ and Carla GS Saad¹, ¹Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil
Background/Purpose: The use of synthetic DMARDS (sDMARDs) in spondyloarthritis (SpA) has been increasingly questioned and restricted to peripheral disease, on the other hand, the use…
Abstract Number: 689 • 2018 ACR/ARHP Annual Meeting
Association of Kinesiophobia, Aerobic Exercise, Functional Impairment and Disease Activity of Patients with Rheumatoid Arthritis and Spondyloarthritis
Daniele Peres¹, Nicolas Tordi², Daniel Wendling³, Yoshimasa Sagawa⁴ and Clément Prati⁵, ¹EA 4267 PEPITE (FHU INCREASE) – Plateforme EPSI, Université de Bourgogne Franche-Comté, Besançon,, France, ²PEPITE EA 4267, Bourgogne Franche-Comté University, Besançon, France, ³Rheumatology, University Hospital - Bourgogne Franche Comté University, Besançon, France, ⁴Laboratoire de l'Exploration Fonctionnelle et Clinique du Mouvement (LEFCM), BESANCON, France, ⁵Rheumatology, University Hospital - Bourgogne Franche Comté University, Besancon, France
Association of kinesiophobia, aerobic exercise, functional impairment and disease activity of patients with rheumatoid arthritis and spondyloarthritis.Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SA) are the…
Abstract Number: 690 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis: 52-Week Results from a Phase 3 Study
Philip J. Mease¹, Désirée van der Heijde², Robert B.M. Landewé³, Shephard Mpofu⁴, Proton Rahman⁵, Hasan Tahir⁶, Atul Singhal⁷, Elke Böttcher⁸, Sandra V. Navarra⁹, Xuan Zhu¹⁰, Aimee Readie¹⁰, Luminita Pricop¹¹ and Ken Abrams¹⁰, ¹Swedish Medical Centre and University of Washington, Seattle, WA, ²Leiden University Medical Centre, Leiden, Netherlands, ³University of Amsterdam, Amsterdam, Netherlands, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Memorial University of Newfoundland and Labrador, St. John's, NF, Canada, ⁶Whipps Cross University Hospital, Barts Health NHS Trust, London, United Kingdom, ⁷Southwest Rheumatology, Dallas, TX, ⁸Rheumazentrum Favoriten, Vienna, Austria, ⁹University of Santo Tomas Hospital, Manila, Philippines, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ
Background/Purpose: Secukinumab (SEC), a fully human anti-interleukin-17A monoclonal antibody, significantly improved signs and symptoms and inhibited radiographic progression versus placebo (PBO) at Week (Wk) 24…
Abstract Number: 691 • 2018 ACR/ARHP Annual Meeting
A Service Evaluation of Reporting Standards of Computer Tomography Defined Sacroiliitis Suggestive of Axial Spondyloarthritis in Inflammatory Bowel Disease Patients Imaged for Non-Musculoskeletal Indications
Chong Seng Edwin Lim¹, Samantha Bee Lian Low², Baljeet Dhillon², Shin Azegami², Andoni Paul Toms² and Karl Gaffney¹, ¹Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ²Radiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom
Background/Purpose: A combined service evaluation by the rheumatology and radiology department was undertaken to understand the frequency and reporting standards of Computer Tomography-defined Sacroiliitis (CTSI)…
Abstract Number: 692 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Daeria O. Lawson^1,2, Maria Eraso³, Lawrence Mbuagbaw⁴, Theresa Aves⁵, Alvin Leenus⁴, Marianinha Joanes⁶, Ahmed Omar^1,7 and Robert D Inman^8,9, ¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ²Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Hamilton, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, Tornoto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, Hamilton, ON, Canada, ⁵St. Michael's Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Boston University School of Medicine, Boston, MA, United States, Boston, MA, ⁷Rheumatology, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁸Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada
Background/Purpose: Patients with axial spondyloarthritis (axSpA) who have achieved a stable disease state and are undergoing treatment with tumour necrosis factor inhibitor (TNFi) therapy may…
Abstract Number: 693 • 2018 ACR/ARHP Annual Meeting
Combining Adalimumab with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®
Omar Benryane¹, Louis Coupal² and Denis Choquette², ¹Médecine, Faculté de Médecine de l’Université de Montréal, Montréal, QC, Canada, ²Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: Psoriatic Arthritis (PsA) in a musculoskeletal inflammatory condition associated with psoriasis. It has a heterogeneous set of clinical manifestations which include peripheral arthritis, axial…
Abstract Number: 694 • 2018 ACR/ARHP Annual Meeting
Combining Etanercept with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®
Omar Benryane¹, Louis Coupal² and Denis Choquette², ¹Médecine, Faculté de Médecine de l’Université de Montréal, Montréal, QC, Canada, ²Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: Psoriatic Arthritis (PsA) in a musculoskeletal inflammatory condition associated with psoriasis. It has a heterogeneous set of clinical manifestations which include peripheral arthritis, axial…
Abstract Number: 695 • 2018 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitor Persistence and Reasons for Discontinuation in US Veterans with Axial Spondyloarthritis
Delamo Bekele¹, Elizabeth Cheng², Christian Geier^3,4, Kavya Ganuthula⁵, Jessica Walsh^6,7, Maureen Dubreuil^8,9, Daniel O. Clegg¹⁰, Prashant Kaushik¹¹, Bernard Ng^12,13,14,15, Elizabeth Chang¹⁶, Andreas Reimold^17,18, Siba P. Raychaudhuri¹⁹, Ryan Duong²⁰, Kristine A Kuhn²¹, Yujin Park²² and Gail S. Kerr²³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, University of Colorado, Denver, CO, ³Rheumatology, Columbia University- NYP Hospital, New York, NY, ⁴Columbia University, New York, NY, ⁵Internal Medicine, VA Eastern Colorado Health Care System, Aurora, CO, ⁶Rheumatology Section, Salt Lake City Veterans Affairs, Salt Lake City, UT, ⁷Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁸Rheumatology, VA Boston Healthcare System & Boston University School of Medicine, Boston, MA, ⁹Rheumatology, VA Boston Healthcare System, Boston, MA, ¹⁰Division of Rheumatology, University of Utah Medical Center, Salt Lake City, UT, ¹¹Rheumatology/Medicine, Stratton VAMC, Albany, NY, ¹²Rheumatology, Seattle VAMC, Seattle, WA, ¹³Rheumatology, VA Puget Sound Healthcare System, Seattle, WA, ¹⁴Michael E. DeBakey VA Medical Center Health Services Research and Development Center of Excellence, Houston, TX, ¹⁵Division of Rheumatology, University of Washington, Seattle, WA, ¹⁶Rheumatology, Phoenix VAHCS, Phoenix, AZ, ¹⁷Rheumatology, Dallas VAMC, Dallas, TX, ¹⁸Rheumatology, Dallas VA Medical Center and University of Texas - Southwestern, Dallas, TX, ¹⁹Rheumatology, Sacramento VAMC, Mather, CA, ²⁰Rheumatology, Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO, ²¹Division of Rheumatology, Rocky Mountain Regional Veterans Affairs Medical Center/University of Colorado School of Medicine, Aurora, CO, ²²Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ²³Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC
Background/Purpose: Although tumor necrosis factor inhibitors (TNFi) have favorably altered the treatment landscape for patients with axial spondyloarthritis (AxSpA), permanent therapy is infrequent. Further, the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].